Profiling critical cancer gene mutations in clinical tumor samples
about
Recurrent BRAF mutations in Langerhans cell histiocytosismTOR inhibitors in advanced renal cell carcinomaGenetics and Epigenetics of Glioblastoma: Applications and Overall Incidence of IDH1 MutationCurrent Challenges in Glioblastoma: Intratumour Heterogeneity, Residual Disease, and Models to Predict Disease RecurrenceENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngiomaClinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challengesWill kinase inhibitors make it as glioblastoma drugs?Advances in the Molecular Analysis of Soft Tissue Tumors and Clinical ImplicationsDissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine.Somatic mutations in solid tumors: a spectrum at the service of diagnostic armamentarium or an indecipherable puzzle? The morphological eyes looking for BRAF and somatic molecular detections on cyto-histological samplesRecent advances in the understanding of Langerhans cell histiocytosisSWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2High-throughput RNA sequencing of a formalin-fixed, paraffin-embedded autopsy lung tissue sample from the 1918 influenza pandemicExome sequencing identifies BRAF mutations in papillary craniopharyngiomasMulti-purpose utility of circulating plasma DNA testing in patients with advanced cancersHigh throughput interrogation of somatic mutations in high grade serous cancer of the ovarySynthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma.Combinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanismsAssessing the clinical utility of cancer genomic and proteomic data across tumor types.High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencingGenetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer.Clinical analysis and interpretation of cancer genome dataSystematic assessment of analytical methods for drug sensitivity prediction from cancer cell line dataEGFR molecular testing in African-American non-small cell lung cancer patients - a review of discrepant data.BRAF V600E-mutated diffuse glioma in an adult patient: a case report and review.OncDRS: An integrative clinical and genomic data platform for enabling translational research and precision medicineOptimization of cell lines as tumour models by integrating multi-omics data.Genotyping cancer-associated genes in chordoma identifies mutations in oncogenes and areas of chromosomal loss involving CDKN2A, PTEN, and SMARCB1Clinical effect of point mutations in myelodysplastic syndromesCTLA4 blockade broadens the peripheral T-cell receptor repertoireA targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practiceThe suitability of matrix assisted laser desorption/ionization time of flight mass spectrometry in a laboratory developed test using cystic fibrosis carrier screening as a model.Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.Analysis and comparison of somatic mutations in paired primary and recurrent epithelial ovarian cancer samples.Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma.Pediatric low-grade gliomas: how modern biology reshapes the clinical field.Precision oncology using a limited number of cells: optimization of whole genome amplification products for sequencing applications.BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications.Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial.
P2860
Q24594344-42421776-00AF-4E0F-B28B-FECBF7CC0CB8Q24612127-BF056992-E5EC-4BC7-A52D-C192A1AFFF49Q26767392-E0D20039-126D-41AC-837A-3CFFA287B479Q26774502-B623A2DB-F8A3-4E40-9B43-60D3F4687A1DQ26777288-702B9D2E-3650-480E-BED2-CDBE8834DE47Q26823978-035D93DF-2DBF-43BB-B887-A46E5210D196Q27012684-5ECA0787-7849-4CB8-9EA7-C1992E5B6D9DQ27021848-E8795235-1289-4279-A455-4B8E6E195A9FQ27851628-00E828D8-C40A-449A-96C3-2F1655495817Q27853005-7F807B30-B923-4458-B2EB-662C111AD0A7Q28070226-1303CDF1-D81F-48B5-9A50-CE852B65C186Q28251005-50EEBD0B-70C4-4C7B-A168-D59D12627FBCQ28269618-F9DC9EC2-D15E-41D5-BA64-5AC29C4352FBQ28279911-4A5560C7-EF11-4109-B279-784338947250Q28305680-E1D767BC-5C39-4E44-A417-AD7EB8855218Q28484970-83B50B72-CFA7-43F6-A070-472D75120FA4Q28740553-7902559E-ADA5-43CE-BEC5-6C2980986CF3Q30416651-C1923EFD-DFC4-4829-BE3D-43D29DAB06BCQ30418057-7C31519A-1B81-4D3D-ACEC-180C8CE25435Q30487077-C0047F3A-C668-4EDB-BB44-495603051A94Q30514084-DFAFA6F4-1C0A-4BE0-B124-240DBCDA9DFBQ30573750-BCFF06E7-C085-4673-8CCB-A65B51375136Q30617093-2E5FFADC-61D3-49DA-B57F-4F6E13158557Q30705777-181B3F3D-9B45-4C61-9EB4-C31F5E74D4CAQ30915526-985BFB46-7B9C-48A6-AECE-B7AB30B6A8FAQ31002780-D89F6525-53BA-43B9-84BD-B5421B81CD27Q31070571-9AEAAC50-E9F8-491E-BB1C-D76370CB4348Q31134293-5BFC56D4-637E-4A58-A5E6-308883E5D006Q33275318-5D36C391-A2A0-4CF7-A2E8-8108AFC9850DQ33395996-C979A6EA-BC39-4401-A708-67C5BA307DCCQ33560753-DE168F5B-1B66-40BD-B795-3F4A93711C44Q33577844-F3D874AD-B0B3-47E9-9733-7A65AA4E0CAFQ33628495-1A5D5A58-3DAB-4474-8750-F1F91E89FB07Q33697252-A0449FC0-98F0-45E1-BE3C-1AA5F4DF8487Q33768759-562CF4AD-60A6-4955-B89F-77CDD883EEC8Q33814916-CF1751AE-38B1-4A58-B8B0-160ECDE01803Q33847771-2BFBD8E6-BCA6-42D4-88BD-E398D9B5BFF9Q33861909-6E0E4FD1-C035-4A0D-AEAE-03B4B02D9ACBQ33867475-4D5797A6-028B-4F97-BC49-9FE604E580C7Q33877385-D6EDEC3E-1D9A-4D8F-A0CB-FF3EE69C6441
P2860
Profiling critical cancer gene mutations in clinical tumor samples
description
2009 nî lūn-bûn
@nan
2009 թուականին հրատարակուած գիտական յօդուած
@hyw
2009 թվականին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Profiling critical cancer gene mutations in clinical tumor samples
@ast
Profiling critical cancer gene mutations in clinical tumor samples
@en
Profiling critical cancer gene mutations in clinical tumor samples
@en-gb
Profiling critical cancer gene mutations in clinical tumor samples
@nl
type
label
Profiling critical cancer gene mutations in clinical tumor samples
@ast
Profiling critical cancer gene mutations in clinical tumor samples
@en
Profiling critical cancer gene mutations in clinical tumor samples
@en-gb
Profiling critical cancer gene mutations in clinical tumor samples
@nl
altLabel
Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples
@en
prefLabel
Profiling critical cancer gene mutations in clinical tumor samples
@ast
Profiling critical cancer gene mutations in clinical tumor samples
@en
Profiling critical cancer gene mutations in clinical tumor samples
@en-gb
Profiling critical cancer gene mutations in clinical tumor samples
@nl
P2093
P2860
P50
P3181
P1433
P1476
Profiling critical cancer gene mutations in clinical tumor samples
@en
P2093
Adam J Bass
Alissa C Baker
Caroline M Emery
Catarina D Campbell
Chandrani Mondal
Charles D Stiles
Charles Hatton
Deborah J Goff
Franco Roviello
Gianni Corso
P2860
P3181
P356
10.1371/JOURNAL.PONE.0007887
P407
P577
2009-01-01T00:00:00Z